| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6094328 | Gastroenterology | 2014 | 43 Pages |
Abstract
Platelets produce PDGFB to activate HSC and promote fibrosis in MDR2-null mice and mice on DDC-supplemented diets. Antiplatelet therapy or selective inhibition of PDGFB might reduce biliary fibrosis in patients with liver disease.
Keywords
α-SMATGFALTPSCASPPDGFmRNAmAbHYPCOXPBCMMPPDGFRHSC3,5-diethoxycarbonyl-1,4-dihydrocollidineddCmessenger RNAChronic liver injuryAlanine aminotransferaseMonoclonal antibodycyclooxygenaseα-smooth muscle actintransforming growth factorEnzyme-linked immunosorbent assayELISAIntraperitoneallyTIMPHepatic stellate cellplatelet-derived growth factormatrix metalloproteinaseMouse modelTissue inhibitor of metalloproteinaseshydroxyprolineplatelet-derived growth factor receptor
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Shuhei Yoshida, Naoki Ikenaga, Susan B. Liu, Zhen-Wei Peng, Jeanhee Chung, Deanna Y. Sverdlov, Makoto Miyamoto, Yong Ook Kim, Shinji Ogawa, Robert H. Arch, Detlef Schuppan, Yury Popov,